SNAPC3

Summary

SNAPC3 (small nuclear RNA activating complex polypeptide 3, HGNC:11136) is a protein-coding gene on chromosome 9p22.3, encoding snRNA-activating protein complex subunit 3 (Q92966). Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. It is a common-essential gene (DepMap: required in 97.9% of cancer cell lines).

Predicted to enable RNA polymerase III type 3 promoter sequence-specific DNA binding activity and bent DNA binding activity. Predicted to contribute to RNA polymerase II cis-regulatory region sequence-specific DNA binding activity and core promoter sequence-specific DNA binding activity. Predicted to be involved in snRNA transcription by RNA polymerase II and snRNA transcription by RNA polymerase III. Located in nuclear body and nucleolus.

Source: NCBI Gene 6619 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 82 total — 2 pathogenic
• Cancer dependency (DepMap): dependent in 97.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_001039697

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11136
Approved symbol	SNAPC3
Name	small nuclear RNA activating complex polypeptide 3
Location	9p22.3
Locus type	gene with protein product
Status	Approved
Aliases	SNAP50, PTFbeta, MGC33124, MGC132011
Ensembl gene	ENSG00000164975
Ensembl biotype	protein_coding
OMIM	602348
Entrez	6619

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000380799, ENST00000380821, ENST00000421710, ENST00000461041, ENST00000467062, ENST00000490969, ENST00000610884, ENST00000892142, ENST00000892143, ENST00000965147, ENST00000965148

RefSeq mRNA: 6 — MANE Select: NM_001039697 NM_001039697, NM_001369647, NM_001369648, NM_001369649, NM_001369650, NM_001369651

CCDS: CCDS6478

Canonical transcript exons

ENST00000380821 — 9 exons

Exon	Start	End
ENSE00001089083	15433552	15433636
ENSE00001089086	15444602	15444706
ENSE00001089102	15451320	15451402
ENSE00001089104	15447095	15447244
ENSE00001486427	15459719	15461626
ENSE00001732177	15457960	15458067
ENSE00001887040	15422876	15423193
ENSE00002716594	15453041	15453205
ENSE00003556953	15423909	15423986

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 93.88.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.9694 / max 270.0191, expressed in 1807 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96145	28.9555	1807
96144	0.0139	4

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	93.88	gold quality
ventricular zone	UBERON:0003053	93.75	gold quality
adrenal tissue	UBERON:0018303	93.19	gold quality
cortical plate	UBERON:0005343	92.58	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.40	gold quality
left testis	UBERON:0004533	92.20	gold quality
right testis	UBERON:0004534	92.18	gold quality
heart right ventricle	UBERON:0002080	92.14	gold quality
testis	UBERON:0000473	91.35	gold quality
calcaneal tendon	UBERON:0003701	90.91	gold quality
embryo	UBERON:0000922	90.27	gold quality
biceps brachii	UBERON:0001507	90.07	gold quality
sural nerve	UBERON:0015488	89.81	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.80	gold quality
pons	UBERON:0000988	89.78	gold quality
tendon	UBERON:0000043	88.90	gold quality
medial globus pallidus	UBERON:0002477	88.86	gold quality
adult organism	UBERON:0007023	88.71	gold quality
right coronary artery	UBERON:0001625	88.30	gold quality
rectum	UBERON:0001052	88.11	gold quality
endometrium	UBERON:0001295	88.10	gold quality
monocyte	CL:0000576	87.88	gold quality
popliteal artery	UBERON:0002250	87.88	gold quality
tibial artery	UBERON:0007610	87.87	gold quality
descending thoracic aorta	UBERON:0002345	87.84	gold quality
aorta	UBERON:0000947	87.76	gold quality
colonic epithelium	UBERON:0000397	87.68	gold quality
thoracic aorta	UBERON:0001515	87.66	gold quality
Brodmann (1909) area 46	UBERON:0006483	87.60	gold quality
globus pallidus	UBERON:0001875	87.58	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.31
E-GEOD-124858	no	114.53

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

86 targeting SNAPC3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-548AV-5P	99.60	70.84	2107

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 97.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 1)

• SNAP50 zinc finger domain contributes to cooperative promoter recognition by human SNAPC (PMID:16901896)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	snapc3	ENSDARG00000101474
mus_musculus	Snapc3	ENSMUSG00000028483
rattus_norvegicus	Snapc3	ENSRNOG00000010825
drosophila_melanogaster	Pbp49	FBGN0260398
caenorhabditis_elegans		WBGENE00011367
caenorhabditis_elegans		WBGENE00015098
caenorhabditis_elegans	snpc-3.2	WBGENE00021667
caenorhabditis_elegans	Y48G1BL.8	WBGENE00255594

Protein

Protein identifiers

snRNA-activating protein complex subunit 3 — Q92966 (reviewed: Q92966)

Alternative names: Proximal sequence element-binding transcription factor subunit beta, Small nuclear RNA-activating complex polypeptide 3, snRNA-activating protein complex 50 kDa subunit

All UniProt accessions (3): Q92966, Q5T282, Q5T284

UniProt curated annotations — full annotation on UniProt →

Function. Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. Binds to the proximal sequence element (PSE), a non-TATA-box basal promoter element common to these 2 types of genes. Recruits TBP and BRF2 to the U6 snRNA TATA box.

Subunit / interactions. Part of the SNAPc complex composed of 5 subunits: SNAPC1, SNAPC2, SNAPC3, SNAPC4 and SNAPC5. SNAPC3 interacts with SNAPC1.

Subcellular location. Nucleus.

Similarity. Belongs to the SNAPC3/SRD2 family.

RefSeq proteins (6): NP_001034786, NP_001356576, NP_001356577, NP_001356578, NP_001356579, NP_001356580 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR022042	snRNA-activating_su3	Family

Pfam: PF12251

UniProt features (42 total): strand 21, helix 11, turn 6, region of interest 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

18 structures.

PDB	Method	Resolution (Å)
7ZWD	ELECTRON MICROSCOPY	3
7ZX8	ELECTRON MICROSCOPY	3
9K3U	ELECTRON MICROSCOPY	3
7ZWC	ELECTRON MICROSCOPY	3.2
9FSO	ELECTRON MICROSCOPY	3.28
9LXN	ELECTRON MICROSCOPY	3.3
9FSP	ELECTRON MICROSCOPY	3.39
7ZX7	ELECTRON MICROSCOPY	3.4
8IUH	ELECTRON MICROSCOPY	3.4
7XUR	ELECTRON MICROSCOPY	3.49
7ZXE	ELECTRON MICROSCOPY	3.5
9K3V	ELECTRON MICROSCOPY	3.5
9FSQ	ELECTRON MICROSCOPY	3.51
9FSR	ELECTRON MICROSCOPY	3.76
8ITY	ELECTRON MICROSCOPY	3.9
8IUE	ELECTRON MICROSCOPY	4.1
9FSS	ELECTRON MICROSCOPY	4.14
9K3B	ELECTRON MICROSCOPY	4.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92966-F1	85.10	0.53

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-6807505	RNA polymerase II transcribes snRNA genes
R-HSA-749476	RNA Polymerase III Abortive And Retractive Initiation
R-HSA-76071	RNA Polymerase III Transcription Initiation From Type 3 Promoter
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74158	RNA Polymerase III Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-76046	RNA Polymerase III Transcription Initiation

MSigDB gene sets: 144 (showing top): REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER, GOZGIT_ESR1_TARGETS_DN, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_III, AACWWCAANK_UNKNOWN, GCM_NF2, BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_UP, CUI_TCF21_TARGETS_2_DN, ACEVEDO_LIVER_CANCER_UP, DANG_BOUND_BY_MYC, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN, PARENT_MTOR_SIGNALING_UP, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, MARSON_BOUND_BY_FOXP3_STIMULATED, BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_UP, BENPORATH_MYC_MAX_TARGETS

GO Biological Process (5): transcription by RNA polymerase II (GO:0006366), transcription by RNA polymerase III (GO:0006383), snRNA transcription (GO:0009301), snRNA transcription by RNA polymerase II (GO:0042795), snRNA transcription by RNA polymerase III (GO:0042796)

GO Molecular Function (7): RNA polymerase III general transcription initiation factor activity (GO:0000995), RNA polymerase III type 3 promoter sequence-specific DNA binding (GO:0001006), DNA binding (GO:0003677), bent DNA binding (GO:0003681), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), core promoter sequence-specific DNA binding (GO:0001046), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), nuclear body (GO:0016604), snRNA-activating protein complex (GO:0019185)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
RNA Polymerase III Transcription	2
Gene expression (Transcription)	2
RNA Polymerase II Transcription	1
RNA Polymerase III Transcription Initiation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	3
snRNA transcription	2
transcription by RNA polymerase III	2
nuclear lumen	2
intracellular membraneless organelle	2
snRNA metabolic process	1
transcription by RNA polymerase II	1
general transcription initiation factor activity	1
RNA polymerase III cis-regulatory region sequence-specific DNA binding	1
nucleic acid binding	1
DNA binding	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
transcription cis-regulatory region binding	1
binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
nucleoplasm	1
transcription regulator complex	1

Protein interactions and networks

STRING

1244 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SNAPC3	SNAPC1	Q16533	999
SNAPC3	SNAPC2	Q13487	999
SNAPC3	SNAPC4	Q5SXM2	997
SNAPC3	SNAPC5	O75971	983
SNAPC3	TBP	P20226	806
SNAPC3	TAF1A	Q15573	681
SNAPC3	POLI	Q9UNA4	597
SNAPC3	ZNF488	Q96MN9	548
SNAPC3	LSM8	O95777	537
SNAPC3	CCDC171	Q6TFL3	475
SNAPC3	ASXL1	Q8IXJ9	473
SNAPC3	TAF1D	Q9H5J8	465
SNAPC3	MNMIP1	A4FU49	451
SNAPC3	TNPO3	Q9Y5L0	449
SNAPC3	SHISA4	Q96DD7	448

IntAct

80 interactions, top by confidence:

A	B	Type	Score
SNAPC1	SNAPC3	psi-mi:“MI:0915”(physical association)	0.850
SNAPC1	SNAPC3	psi-mi:“MI:0914”(association)	0.850
SNAPC4	SNAPC1	psi-mi:“MI:0914”(association)	0.790
SNAPC1	SNAPC5	psi-mi:“MI:0914”(association)	0.740
SNAPC1	SNAPC5	psi-mi:“MI:0915”(physical association)	0.740
HSD17B14	SNAPC3	psi-mi:“MI:0915”(physical association)	0.670
SNAPC3	HSD17B14	psi-mi:“MI:0915”(physical association)	0.670
CEP57L1	SNAPC3	psi-mi:“MI:0915”(physical association)	0.560
SNAPC3	CEP57L1	psi-mi:“MI:0915”(physical association)	0.560
TTC4	SNAPC3	psi-mi:“MI:0915”(physical association)	0.560
NFKBID	SNAPC3	psi-mi:“MI:0915”(physical association)	0.560
UBE3A	SNAPC3	psi-mi:“MI:0915”(physical association)	0.560
ZNF620	SNAPC3	psi-mi:“MI:0915”(physical association)	0.560
SNAPC3	KATNBL1	psi-mi:“MI:0915”(physical association)	0.560
SNRNP35	SNAPC3	psi-mi:“MI:0915”(physical association)	0.560
SNAPC3		psi-mi:“MI:0915”(physical association)	0.560
SNAPC3	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
NEFL	SNAPC3	psi-mi:“MI:0915”(physical association)	0.560
SNAPC3	WFS1	psi-mi:“MI:0915”(physical association)	0.560
SNAPC3	KIF1B	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (64): HSD17B14 (Two-hybrid), CEP57L1 (Two-hybrid), SNAPC3 (Affinity Capture-MS), SNAPC3 (Affinity Capture-MS), SNAPC3 (Affinity Capture-MS), SNAPC3 (Affinity Capture-MS), SNAPC3 (Affinity Capture-MS), SNAPC3 (Two-hybrid), SNAPC3 (Two-hybrid), SNAPC3 (Two-hybrid), NFKBID (Two-hybrid), ZNF620 (Two-hybrid), SNRNP35 (Two-hybrid), TTC4 (Two-hybrid), SNAPC3 (Two-hybrid)

ESM2 similar proteins: A0A087WRI3, A2AIP0, A4IFQ0, A8MTA8, H3BNL1, O70373, O95983, P21580, P55199, Q0VB26, Q1JQA1, Q1RMS8, Q2TA11, Q2TBR5, Q3B7L5, Q3ZK22, Q4R6Y6, Q4R8W3, Q4VA36, Q5RFL7, Q5XI52, Q60769, Q62522, Q68FX7, Q69Z89, Q6ZQR2, Q702N8, Q76JQ2, Q7Z6J9, Q86UT8, Q8CEG5, Q8CHQ0, Q8IW40, Q8N1D5, Q8N6G2, Q8N801, Q8NFG4, Q8QZS3, Q91Z62, Q91ZP9

Diamond homologs: Q4R6Y6, Q5BK68, Q5E9M5, Q8L627, Q92966, Q9D2C9

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SNAPC3	“form complex”	SNAPC	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	67
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
562130	GRCh37/hg19 9p23-22.2(chr9:14178768-16619009)x1	Pathogenic
59101	GRCh38/hg38 9p23-22.2(chr9:11818291-17963882)x1	Pathogenic

SpliceAI

1797 predictions. Top by Δscore:

Variant	Effect	Δscore
9:15423907:A:AG	acceptor_gain	1.0000
9:15423908:G:GG	acceptor_gain	1.0000
9:15423908:GCCTT:G	acceptor_gain	1.0000
9:15423987:G:GA	donor_loss	1.0000
9:15433540:C:G	acceptor_gain	1.0000
9:15433547:AACAG:A	acceptor_gain	1.0000
9:15433550:AG:A	acceptor_gain	1.0000
9:15433551:GG:G	acceptor_gain	1.0000
9:15433633:GATG:G	donor_gain	1.0000
9:15444597:TTCAG:T	acceptor_loss	1.0000
9:15444598:TCAG:T	acceptor_loss	1.0000
9:15444598:TCAGG:T	acceptor_gain	1.0000
9:15444599:CAGG:C	acceptor_gain	1.0000
9:15444600:A:AG	acceptor_gain	1.0000
9:15444600:A:C	acceptor_loss	1.0000
9:15444600:AG:A	acceptor_gain	1.0000
9:15444600:AGGA:A	acceptor_gain	1.0000
9:15444601:G:A	acceptor_gain	1.0000
9:15444601:G:GA	acceptor_gain	1.0000
9:15444601:G:T	acceptor_loss	1.0000
9:15444601:GGA:G	acceptor_gain	1.0000
9:15444601:GGAG:G	acceptor_gain	1.0000
9:15444601:GGAGT:G	acceptor_gain	1.0000
9:15444702:ATAAG:A	donor_gain	1.0000
9:15444703:TAAG:T	donor_gain	1.0000
9:15444704:AAG:A	donor_gain	1.0000
9:15444705:AG:A	donor_gain	1.0000
9:15444705:AGG:A	donor_loss	1.0000
9:15444706:GG:G	donor_gain	1.0000
9:15444707:G:GG	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000037035 (9:15443854 A>G), RS1000141949 (9:15439421 C>G,T), RS1000184641 (9:15432547 T>C), RS1000221548 (9:15435155 C>A,T), RS1000257620 (9:15430899 A>G), RS1000302981 (9:15464403 A>G,T), RS1000362100 (9:15426068 G>C,T), RS1000382412 (9:15448963 T>C), RS1000394004 (9:15422327 C>G,T), RS1000416291 (9:15426237 C>G,T), RS1000502696 (9:15445506 A>G,T), RS1000539947 (9:15441390 T>TTTC), RS1000664276 (9:15440571 G>A,T), RS1000673489 (9:15436662 T>C), RS1000721926 (9:15435444 C>T)

Disease associations

OMIM: gene MIM:602348 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases expression	5
sodium arsenite	affects cotreatment, increases abundance, increases expression, affects expression	2
entinostat	decreases expression, affects cotreatment	2
Aflatoxin B1	decreases methylation, increases expression, increases methylation	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
titanium dioxide	decreases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Carmustine	increases expression	1
Cisplatin	increases response to substance	1
Coumestrol	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Hydrogen Peroxide	increases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Nickel	decreases expression	1
Nicotine	increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders